CLINICAL TRIALS PROFILE FOR NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for naloxone hydrochloride; pentazocine hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00125931 ↗ | Effects of Pentazocine on Manic Symptoms | Completed | Stanley Medical Research Institute | Phase 2 | 2005-09-01 | The opiate neurotransmitter system is thought to be involved in many abnormal mood states. Some researchers have suggested that changes in this system may trigger the switch to/from manic and depressive states in bipolar disorder. One problem with most of the currently available opiate medications is that they can produce addiction/dependence. A particular kind of opiate medication known as kappa-opiates may be able to produce changes in this system with much less risk of addiction. This study looks at Talwin (a combination of pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The study will examine whether two doses of Talwin affect manic symptoms in people who have been admitted to the hospital. This study will give more information about the involvement of the opiate system in bipolar disorder, and give important information for use in developing new treatments. |
| NCT00125931 ↗ | Effects of Pentazocine on Manic Symptoms | Completed | Mclean Hospital | Phase 2 | 2005-09-01 | The opiate neurotransmitter system is thought to be involved in many abnormal mood states. Some researchers have suggested that changes in this system may trigger the switch to/from manic and depressive states in bipolar disorder. One problem with most of the currently available opiate medications is that they can produce addiction/dependence. A particular kind of opiate medication known as kappa-opiates may be able to produce changes in this system with much less risk of addiction. This study looks at Talwin (a combination of pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The study will examine whether two doses of Talwin affect manic symptoms in people who have been admitted to the hospital. This study will give more information about the involvement of the opiate system in bipolar disorder, and give important information for use in developing new treatments. |
| NCT02070718 ↗ | Effects of a Kappa Agonist on Hot Flashes in Menopausal Women | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 | 2013-01-01 | Studies suggest that kappa agonists (KA) and peripherally restricted kappa agonists (PRKAs) may affect thermoregulation. This pilot study has the aim to establish proof of concept regarding efficacy of an oral kappa agonist (KA) for the treatment of menopausal hot flashes. |
| NCT02070718 ↗ | Effects of a Kappa Agonist on Hot Flashes in Menopausal Women | Completed | National Center for Advancing Translational Science (NCATS) | Phase 1 | 2013-01-01 | Studies suggest that kappa agonists (KA) and peripherally restricted kappa agonists (PRKAs) may affect thermoregulation. This pilot study has the aim to establish proof of concept regarding efficacy of an oral kappa agonist (KA) for the treatment of menopausal hot flashes. |
| NCT02070718 ↗ | Effects of a Kappa Agonist on Hot Flashes in Menopausal Women | Completed | National Center for Complementary and Integrative Health (NCCIH) | Phase 1 | 2013-01-01 | Studies suggest that kappa agonists (KA) and peripherally restricted kappa agonists (PRKAs) may affect thermoregulation. This pilot study has the aim to establish proof of concept regarding efficacy of an oral kappa agonist (KA) for the treatment of menopausal hot flashes. |
| NCT02070718 ↗ | Effects of a Kappa Agonist on Hot Flashes in Menopausal Women | Completed | National Institute on Aging (NIA) | Phase 1 | 2013-01-01 | Studies suggest that kappa agonists (KA) and peripherally restricted kappa agonists (PRKAs) may affect thermoregulation. This pilot study has the aim to establish proof of concept regarding efficacy of an oral kappa agonist (KA) for the treatment of menopausal hot flashes. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for naloxone hydrochloride; pentazocine hydrochloride
Condition Name
Clinical Trial Locations for naloxone hydrochloride; pentazocine hydrochloride
Trials by Country
Clinical Trial Progress for naloxone hydrochloride; pentazocine hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for naloxone hydrochloride; pentazocine hydrochloride
Sponsor Name
| Sponsor Name for naloxone hydrochloride; pentazocine hydrochloride | |
| Sponsor | Trials |
| National Center for Advancing Translational Science (NCATS) | 1 |
| National Center for Complementary and Integrative Health (NCCIH) | 1 |
| National Institute on Aging (NIA) | 1 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
